BioCardia (NASDAQ:BCDA) Posts Earnings Results, Misses Expectations By $0.04 EPS

BioCardia (NASDAQ:BCDA) announced its quarterly earnings results on Friday. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04), FiscalAI reports.

Here are the key takeaways from BioCardia’s conference call:

• BioCardia said the CardiAMP heart failure data showed compelling benefits versus control, including reduced adverse remodeling and a statistically significant composite outcome in a high-risk biomarker subgroup.
• The company reported that Japan’s PMDA is inclined to accept the trial data as the basis for a regulatory submission and initial approval, and BioCardia is preparing a Shonin application over the next ~7 months.
• BioCardia said the FDA found the safety profile acceptable and discussed a pre-market approval pathway, while encouraging completion of the ongoing CardiAMP Heart Failure II study to support the filing.
• For its Helix delivery system, FDA indicated no safety or compatibility concerns and suggested potential approval paths, including aligning it with CardiAMP or pursuing a standalone de novo route.
• First-quarter 2026 expenses fell year over year to $2.3 million, with net loss improving to $2.3 million, but cash and cash equivalents ended at only $951,000, underscoring the company’s need for additional funding.

BioCardia Stock Performance

NASDAQ BCDA traded down $0.08 during trading hours on Friday, hitting $1.01. 311,625 shares of the company’s stock traded hands, compared to its average volume of 334,365. The business’s fifty day moving average price is $1.18 and its two-hundred day moving average price is $1.26. BioCardia has a 52 week low of $1.00 and a 52 week high of $2.49.

Institutional Trading of BioCardia

Large investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers purchased a new position in BioCardia during the second quarter valued at approximately $40,000. DRW Securities LLC purchased a new position in BioCardia during the fourth quarter valued at approximately $72,000. Finally, Geode Capital Management LLC lifted its holdings in BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares in the last quarter. 20.57% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $25.00.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.